Myriad Genetics
 | |
| Company type | Public |
|---|---|
| Industry | Health Care biopharmaceutical biotech |
| Founded | Salt Lake City, Utah, USA (1992) |
| Headquarters |  Salt Lake City, Utah, USA |
Key people | Walter Gilbert, Co-Founder, Director, and Vice Chair |
| Website | www.myriad.com |
Myriad Genetics is a biopharmaceutical company.
Current
Today Myriad has a range of cancer predictive medicine products and develop therapeutics that include drug candidates in the areas of Alzheimer's disease and cancer. Individuals with a history of cancer in their family use these products to determine their own risk of developing cancer. Risk can be managed and cancer may be averted through appropriate precautions. If the disease is diagnosed early, it may be treated more successfully through a variety of proven options.
Products (commercial section, no information provided at all
History (advertisement and commercial removed)
In 1980, DNA dignitaries hosted a gathering in Cold Spring Laboratory in New York called “The Molecular Biology of Homo Sapiens.” Nobelaureate Dr. Walter Gilbert proposed a “blind sequencing” project with private financing. Despite his estimate of $3 billion to map the human genome, Gilbert was convinced of the opportunity.[1] In 1992, Dr. Gilbert co-founded Myriad, along with Kevin Kimberlin and Mark Skolnick.
External links
^
- ^ p. 15 ”Cracking the Genome”, by Kevin Davies”